Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Intellia Therapeutics Inc (Intellia Therapeutics) is a clinical-stage gene editing company focused on developing medicines with CRISPR-based therapies. The company's products include Lonvoguran Ziclumeran for the treatment of hereditary angioedema and Nexiguran Ziclumeran for the treatment of transthyretin amyloidosis. Intellia Therapeutics is also developing pipeline for the indication of hemophilia B. It works in partnership with Regeneron, ReCode Therapeutics, SparingVision, ONK Therapeutics, Kyverna, and AvenCell to develop drugs. Intellia is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
40 Erie St Ste 130, Cambridge, Massachusetts, 02139-4254
Website
www.intelliatx.com
Telephone
1 857 2856200
No of Employees
377
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NTLA (NASD)
Revenue (2024)
$67.7M
16.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
20.5%
(2024 vs 2023)
Market Cap*
$1.7B
Net Profit Margin (2024)
XYZ
32.0%
(2024 vs 2023)
* As of and is in US$
Intellia Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Lonvoguran Ziclumera: Hereditary Angioedema |
| Nexiguran Ziclumeran: Transthyretin (ATTR) Amyloidosis |
| Hemophilia B: |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In November, the company received a grant from the US Food and Drug Administration for a Regenerative Medicine Advanced Therapy designation to nexiguran ziclumeran (nex-z, also known as NTLA-2001) to treat hereditary transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN). |
| 2024 | Regulatory Approval | In July, the company received the authorization for its Clinical Trial Application from the United Kingdom’s Medicine and Healthcare Products Regulatory Agency to initiate a Phase 1/2 study evaluating NTLA-3001 to treat alpha-1 antitrypsin deficiency (AATD)-associated lung disease. |
| 2024 | Contracts/Agreements | In February, the company and ReCode Therapeutics entered into a partnership to advance novel genomic medicines for the treatment of cystic fibrosis. |
Competitor Comparison
| Key Parameters | Intellia Therapeutics Inc | Pfizer Inc | Bayer AG | Novo Nordisk AS | Takeda Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Germany | Denmark | Japan |
| City | Cambridge | New York City | Leverkusen | Bagsvaerd | Chuo-Ku |
| State/Province | Massachusetts | New York | Nordrhein-Westfalen | - | Tokyo |
| No. of Employees | 377 | 75,000 | 87,830 | 64,974 | 47,029 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Frank Verwiel, M.D. | Chairman | Executive Board | 2017 | 63 |
| John M. Leonard, M.D | President; Director; Chief Executive Officer | Executive Board | 2014 | 68 |
| Edward J. Dulac | Executive Vice President; Chief Financial Officer | Senior Management | 2024 | 51 |
| David Lebwohl, M.D. | Executive Vice President; Chief Medical Officer | Senior Management | 2020 | 71 |
| Birgit Schultes, Ph.D. | Chief Scientific Officer; Executive Vice President | Senior Management | 2025 | 63 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer